Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/29/23
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023GlobeNewsWire • 09/27/23
Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology PipelineSeeking Alpha • 09/22/23
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023GlobeNewsWire • 09/07/23
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/06/23
Cidara Therapeutics Announces Janssen's Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting InfluenzaGlobeNewsWire • 09/06/23
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & DevelopmentGlobeNewsWire • 08/16/23
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/03/23
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza ProgramGlobeNewsWire • 07/20/23
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and BGlobeNewsWire • 06/22/23
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy SummitGlobeNewsWire • 06/20/23
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy SummitGlobeNewsWire • 06/13/23
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/11/23
Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases ConferenceGlobeNewsWire • 05/03/23
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™GlobeNewsWire • 04/24/23